MX2009000950A - Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos. - Google Patents

Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.

Info

Publication number
MX2009000950A
MX2009000950A MX2009000950A MX2009000950A MX2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A MX 2009000950 A MX2009000950 A MX 2009000950A
Authority
MX
Mexico
Prior art keywords
glucocorticoid receptor
mammalian subject
treatment
infectious conditions
receptor antagonists
Prior art date
Application number
MX2009000950A
Other languages
English (en)
Inventor
B W M M Bernardus Peeters
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of MX2009000950A publication Critical patent/MX2009000950A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona el uso de un antagonista del receptor de glucocorticoide para la manufactura de un medicamento para el estímulo inmune, tal como la prevención o tratamiento de infecciones o condiciones infecciosas, en un sujeto mamífero de edad avanzada, un sujeto mamífero con bajos valores de suero DHEAS, un sujeto mamífero con una alta proporción en suero de cortisol/DHEAS, o un sujeto mamífero con cuentas altas de neutrófilos. En particular el antagonista del receptor de glucocorticoide puede ser seleccionado del grupo consistente de un derivado de dibenzopiranil definido y/o ejemplificado en la Patente Norteamericana US 6329534 y el documento WO2001116128, mifepristona, y (11ß, 17ß)-11-(1,3-benzodioxol-5-il)-17-hidroxi-17 -(1-propinil)estra-4,9-dien-3-ona.
MX2009000950A 2006-08-08 2007-08-06 Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos. MX2009000950A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06118587 2006-08-08
PCT/EP2007/058134 WO2008017658A2 (en) 2006-08-08 2007-08-06 Use of glucocorticoid receptor antagonists for treatment of infectious conditions

Publications (1)

Publication Number Publication Date
MX2009000950A true MX2009000950A (es) 2009-02-04

Family

ID=37600754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000950A MX2009000950A (es) 2006-08-08 2007-08-06 Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.

Country Status (13)

Country Link
US (1) US20100075936A1 (es)
EP (2) EP2204171A1 (es)
JP (1) JP2010500323A (es)
KR (1) KR20090039775A (es)
CN (1) CN101500547A (es)
AR (1) AR062229A1 (es)
AU (1) AU2007283604A1 (es)
CA (1) CA2658016A1 (es)
IL (1) IL196392A0 (es)
MX (1) MX2009000950A (es)
TW (1) TW200820977A (es)
WO (1) WO2008017658A2 (es)
ZA (1) ZA200900242B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2742964C (en) 2008-11-07 2020-07-07 University Of Sheffield Medicament and method of diagnosis
WO2012135274A1 (en) 2011-03-31 2012-10-04 Pop Test Cortisol Llc Prevention of infection
EP2699245A4 (en) * 2011-04-18 2014-12-10 Pop Test Cortisol Llc TREATMENT AGAINST HAIR LOSS
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
EP3400233A4 (en) * 2015-08-03 2020-02-26 Pop Test Oncology LLC PHARMACEUTICAL COMPOSITIONS AND METHODS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
ES2092958B1 (es) * 1995-01-10 1997-08-01 Miret Lab Procedimiento para la sintesis de tensioactivos cationicos derivados de la condensacion de acidos grasos con aminoacidos de caracter basico esterificados y su aplicacion como agentes antimicrobianos.
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
EP0954317B1 (en) 1996-04-09 2007-06-06 The University Of Edinburgh Use of 7 apha-substituted steroids to treat neuropsychiatric disorders
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
US6329534B1 (en) 1999-09-01 2001-12-11 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
US8388986B2 (en) * 2001-08-09 2013-03-05 Laboratorios Miret S.A. Use of cationic surfactants in cosmetic preparations
WO2003034842A1 (en) * 2001-10-25 2003-05-01 Laboratorios Miret, S.A. Use of cationic preservative in food products
AU2002358540A1 (en) * 2001-11-30 2003-06-10 Solvay Pharmaceuticals Gmbh Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
CN101119970A (zh) * 2004-01-09 2008-02-06 科赛普特治疗学股份有限公司 氮杂萘烷糖皮质激素受体调节剂
JP4797326B2 (ja) * 2004-01-27 2011-10-19 大正製薬株式会社 生薬含有組成物

Also Published As

Publication number Publication date
EP2204171A1 (en) 2010-07-07
CA2658016A1 (en) 2008-02-14
JP2010500323A (ja) 2010-01-07
ZA200900242B (en) 2011-06-29
CN101500547A (zh) 2009-08-05
US20100075936A1 (en) 2010-03-25
IL196392A0 (en) 2009-09-22
WO2008017658A2 (en) 2008-02-14
EP2051705A2 (en) 2009-04-29
AR062229A1 (es) 2008-10-22
AU2007283604A1 (en) 2008-02-14
KR20090039775A (ko) 2009-04-22
TW200820977A (en) 2008-05-16
WO2008017658A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
MX2009000950A (es) Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.
RS51369B (en) ANTAGONISTI RECEPTORA PROGESTERONA
CL2012002722A1 (es) Forma farmaceutica parenteral que libera un inhibidor de aromatasa tal como anastrozol y exemestano, y un gestageno tal como levonorgestrel y gestodeno; y su uso para el tratamiento simultaneo de endometriosis y para la anticoncepcion.
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2005011617A3 (en) Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
PT1421099E (pt) Esteres de 17-alfa, 21-di-hidroxipregneno como agentes anti-androgenicos
HK1087357A1 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1- propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder.
BR0214643A (pt) Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
MX2008000874A (es) Metodos y composiciones para anticoncepcion de emergencia utilizando antagonistas del receptor de endotelina.
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
CA2459033A1 (en) Methods for inhibiting cognitive deterioration in adults with down's syndrome
ATE500834T1 (de) Kontrazeptivum
AR044450A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
김성훈 Visanne®: New treatment option for endometriosis
DK1910398T3 (da) 17-alfa-substituerede derivater af estradiol med sårhelende virkning
ECSP10010152A (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
CU20100084A7 (es) Uso de un gestágeno en combinación con un estrógeno y uno o varios excipientes/portadores farmacéuticamente aceptables para la anticoncepción oral sin lactosa
AU2002325745A1 (en) Protopanaxadiol and protopanaxatriol and their use as synergistic anti-cancer agents
TW200705638A (en) Electrostatic discharge device with controllable holding current
UA44634U (uk) 16Е-(4'-МЕТОКСИБЕНЗИЛІДЕН)-1,3,5(10)-ТРИЄН-3,17β-ДІОЛ, ЩО ВИЯВЛЯЄ АНТИОКСИДАНТНУ АКТИВНІСТЬ ТА ГАЛЬМУЄ РОЗВИТОК ПОСТМЕНОПАУЗАЛЬНОГО МЕТАБОЛІЧНОГО СИНДРОМУ

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: POP TEST CORTISOL LLC

FA Abandonment or withdrawal